1. P1114: ZANDELISIB ON INTERMITTENT DOSING AS A SINGLE AGENT OR IN COMBINATION WITH RITUXIMAB OR ZANUBRUTINIB IN RELAPSED/REFRACTORY (R/R) FOLLICULAR LYMPHOMA (FL): RESULTS FROM A MULTI-ARM PHASE 1B STUDY. (23rd June 2022) Authors: Soumerai, J. D.; Jagadeesh, D.; Salman, H.; Samaniego, F.; Patel, K.; Stathis, A.; Reddy, N.; Kenkre, V. P.; Asch, A.; Diefenbach, C.; Lossos, I. S.; Persky, D.; Awan, F.; Huang, W.; Vandever, K.; Zelenetz, A. D. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 1004 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. P687: A PHASE 1 STUDY WITH THE NOVEL B-CELL LYMPHOMA 2 (BCL2) INHIBITOR BGB-11417 AS MONOTHERAPY OR IN COMBINATION WITH ZANUBRUTINIB (ZANU) IN PATIENTS (PTS) WITH B-CELL MALIGNANCIES: PRELIMINARY DATA. (23rd June 2022) Authors: Opat, S.; Cheah, C. Y.; Lasica, M.; Verner, E.; Browett, P. J.; Chan, H.; Soumerai, J. D.; González Barca, E.; Hilger, J.; Fang, Y.; Huang, J.; Simpson, D.; Tam, C. S. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 583 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. ZANDELISIB, A PI3Kδ INHIBITOR ON INTERMITTENT SCHEDULE (IS) IN FOLLICULAR LYMPHOMA PATIENTS WHO PROGRESSED WITHIN 24 MONTHS OF FIRST‐LINE CHEMOIMUNOTHERAPY (POD24). (17th June 2021) Authors: Pagel, J.; Reddy, N.; Jagadeesh, D.; Stathis, A.; Asch, A. S.; Salman, H.; Kenkre, V. P.; Soumerai, J. D.; Llorin‐Sangalang, J.; Gorbatchevsky, I.; Li, J.; Zelenetz, A. D. Journal: Hematological oncology Issue: Volume 39(2021)Supplement 2 Page Start: n/a Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗